Overcoming The Red Tape Of Regulation Opens Up A Huge Opportunity
The medical cannabis market is growing. And it’s growing fast.
Forecasts suggest it could be worth a staggering $82.2 billion by 2027.
There’s no wonder- barriers are breaking down all the time.
Where ten years ago the use of medical cannabis seemed strange, or even forbidden, more and more people are using it today as the norm.
Indeed, the demand for natural therapeutics has never been higher. It’s one of the reasons states across America are pushing for more relaxed regulation.
But on that front, there is still a problem.
You see, regulation through the Food and Drug Administration (FDA), is slow. Really slow.
And it’s not just approval that’s slow. Even the research and testing of cannabis-based medicines often gets held up in red tape. Frankly, it can take years to get anywhere near a breakthrough.
In fact, it could be a game-changer for our understanding of medical cannabis.
And the good news for investors is it could mean the sky’s the limit for this hugely undervalued Californian company.
Because Juva Life (CSE:JUVA | OTCQB:JUVAF) is developing unique cannabis formulations using industry standard practices more commonly found in the pharmaceutical industry and consistent with FDA best practices.
And, because of the regulatory forbearance that cannabis operates under, they can do real world testing at a fraction of the time and cost of traditional drug development.
A PIONEERING MEDICAL CANNABIS MOGUL MAKES HIS NEXT MOVE
Well, in large part, it’s all down to the vast experience and insight of its founder and CEO, Doug Chloupek.
Chloupek is as close to a legend in the medical cannabis space as you can get.
He was a key part of the team that received California’s first-ever license for the research and manufacture of medical cannabis in 2016.
Indeed, he’s assembled a world-leading team of scientists and medical cannabis experts to help create a range of precision cannabis products.
These are unique cannabis formulations designed to target specific ailments in specific people.
AS CHLOUPEK POINTS OUT, HE WANTS TO “FOLLOW THE EXCITING OPPORTUNITIES OCCURRING IN PRECISION MEDICINE AND DRUG DEVELOPMENT TO DEVELOP EVIDENCE-BASED PRODUCTS THAT WORK.”
Key to Chloupek’s plan is the assembling of a team of experienced individuals. Leading the science advisory board is Guy Miller, MD, PhD, who holds a PhD in chemistry. He is joined by industry veteran Sanjeev Gangwar, PhD, who holds over 40 patents in the pharmaceutical sciences. Rounding out the team is Rakesh Patel, MD, a board certified oncologist with significant clinical science and translational medicine expertise.
And it’s not to even mention the tremendous business insight and understanding, specifically of the medical cannabis industry, that Chloupek has brought on board.
But let’s be honest…
This level of expertise, not to mention the huge amount of research and development required to create new innovations does not come cheap.
But here, Chloupek has yet another ace up his sleeve…
READ OUR DEEP DIVE INTO THE UNIQUE PATHWAY JUVA LIFE HAS CREATED TO ROLL-OUT A RANGE OF LIFE-CHANGING MEDICAL CANNABIS PRODUCTS.
Revenue generating learning
It is a vertically integrated translational learning biosciences company – one of the first of its kind.
In fact, it was just recently granted a license for the cultivation of cannabis at its huge new 30,000 sqft facility in Stockton, California. Plants will soon be in the ground here, and, when fully operational, the facility has the capacity to produce approximately 6,000 pounds of high-quality cannabis flower annually.
You see, Chloupek understands that ground breaking strategies are not enough. There must be a way to both preserve and grow shareholder value avoiding the pitfalls of current cannabis companies (low evidentiary standards) and/or biotechnologies companies (high risk (Eroom’s law) and protracted time lines).
Too many companies in the cannabis space lose because either they cannot control manufacturing and distribution- assuring a steady revenue stream, or they cannot develop durable and proprietary evidenced-based products.
It’s why Chloupek is future-proofing Juva Life (CSE:JUVA | OTCQB:JUVAF) by creating five different, end-to end, arms of the business: Juva Manufacturing, Juva Cultivation, Juva Distribution, Juva Delivery and Juva Retail.
BIG PHARMA WILL BE WATCHING.
With the whole supply chain under control…
With rising demand for its products…
With a superstar team of experts behind the scenes…
With a clear path to significant revenue…
And accelerated time lines for discovery of important and valuable products…
And smart investors will see it makes sense to get in now.
But it’s not just private investors who will be eyeing up this clearly undervalued Californian company…
Big Pharma will no doubt be watching very closely.
Cannabis represents an untapped treasure of potential new products and business models in which to mine them. Juva Life (CSE:JUVA | OTCQB:JUVAF) has figured out how to do both. Based on accelerating value creation by leap-frogging over unapplicable elements costly and time-consuming drug development processes, Juva is able to get real world data at a fraction of the cost and time of their pharmaceutical counterparts. This means lower business and technical risk, with more shots-on-goal, that translates to faster value creation.
And he sees physicians wanting to adopt the portfolio of products to patients looking for naturally derived medicines.
After all, patients are already resorting to cannabis products when conventional drugs fail, but excluding healthcare providers from these decisions.
Bottom line is, Chloupek and his team know this industry…
They are already proven in it…
This is your chance to get in on the action before the mainstream catches wind of it.
Don’t miss the ride.
CLICK HERE TO READ HOW JUVA LIFE IS NOT ONLY REVOLUTIONIZING THE MEDICAL CANNABIS INDUSTRY, BUT IS FUNDING IT ON ITS OWN.
IMPORTANT NOTICE AND DISCLAIMER
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by JUVA LIFE INC. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.